SSG
VTGN icon

Summit Securities Group’s VistaGen Therapeutics VTGN Stock Holding History

Summit Securities Group’s Portfolio VTGN Stock Details VTGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-3
Closed – – 1331
2022
Q4 		$0 Sell
3
-15
-83% -$56 ﹤0.01% 1395
2022
Q3 		$0 Buy
+18
New +$178 ﹤0.01% 1183

Other funds holding VTGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Summit Securities Group's VTGN Position: Q1 2023 in Review

Summit Securities Group sold out of VistaGen Therapeutics (VTGN) in Q1 2023, closing a stake of 3 shares.

Summit Securities Group first reported a position in VTGN in Q3 2022 and held it in 2 quarters. The position peaked at $0 in Q4 2022. 83 funds tracked by Wall St. Rank hold VTGN as of Q1 2023.

  • Summit Securities Group reported no remaining VistaGen Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Summit Securities Group sold 3 VistaGen Therapeutics shares in Q1 2023.
  • Summit Securities Group first reported a position in VistaGen Therapeutics in Q3 2022 and held it in 2 quarters.
  • Summit Securities Group's VistaGen Therapeutics position peaked at $0 in Q4 2022.
  • 83 funds tracked by Wall St. Rank held VistaGen Therapeutics as of Q1 2023.

Based on Summit Securities Group's 13F filing for Q1 2023, filed 12 May 2023.